About SCYNEXIS, Inc.
https://www.scynexis.comSCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC).
CEO
David Gonzalez Angulo
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-07-17 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
AVIDITY PARTNERS MANAGEMENT LP
Shares:3.35M
Value:$2.19M
KINGDON CAPITAL MANAGEMENT, L.L.C.
Shares:2.24M
Value:$1.46M
VANGUARD GROUP INC
Shares:1.76M
Value:$1.15M
Summary
Showing Top 3 of 51
About SCYNEXIS, Inc.
https://www.scynexis.comSCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC).
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $334K ▼ | $8.74M ▼ | $-8.59M ▼ | -2.57K% ▼ | $-0.17 ▼ | $-186K ▼ |
| Q2-2025 | $1.36M ▲ | $10.93M ▲ | $-6.88M ▼ | -504.77% ▲ | $-0.14 ▼ | $2.68M ▼ |
| Q1-2025 | $257K ▼ | $8.87M ▼ | $-5.39M ▼ | -2.1K% ▼ | $-0.11 ▲ | $3.39M ▲ |
| Q4-2024 | $977K ▲ | $9.03M ▼ | $-4.43M ▼ | -453.74% ▼ | $-0.12 ▼ | $-3.73M ▼ |
| Q3-2024 | $660K | $10.98M | $-2.81M | -425.45% | $-0.06 | $-2.99M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $38.01M ▼ | $51.07M ▼ | $14.64M ▼ | $36.43M ▼ |
| Q2-2025 | $44.78M ▲ | $60.69M ▼ | $16.23M ▼ | $44.47M ▼ |
| Q1-2025 | $40.61M ▼ | $67.92M ▼ | $17.38M ▼ | $50.53M ▼ |
| Q4-2024 | $59.3M ▼ | $90.64M ▼ | $35.57M ▼ | $55.08M ▼ |
| Q3-2024 | $68.83M | $99.04M | $40.51M | $58.53M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-8.59M ▼ | $-8.72M ▼ | $12.42M ▲ | $29K ▲ | $3.72M ▼ | $-8.72M ▼ |
| Q2-2025 | $-6.88M ▼ | $-7.5M ▼ | $11.27M ▼ | $0 ▲ | $3.78M ▲ | $-7.5M ▼ |
| Q1-2025 | $-5.39M ▼ | $-7.46M ▲ | $12.44M ▲ | $-14.08M ▼ | $-9.11M ▲ | $-7.46M ▲ |
| Q4-2024 | $-4.43M ▼ | $-9.91M ▼ | $-2.62M ▼ | $-155K ▼ | $-12.68M ▼ | $-9.91M ▼ |
| Q3-2024 | $-2.81M | $765K | $1.94M | $31K | $2.74M | $765K |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 License and Service | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
David Gonzalez Angulo
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-07-17 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
AVIDITY PARTNERS MANAGEMENT LP
Shares:3.35M
Value:$2.19M
KINGDON CAPITAL MANAGEMENT, L.L.C.
Shares:2.24M
Value:$1.46M
VANGUARD GROUP INC
Shares:1.76M
Value:$1.15M
Summary
Showing Top 3 of 51